Serina Therapeutics, Inc. (SER) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Serina Therapeutics, Inc. (SER) closed at USD 1.71 on 2026-10-14, a change of -66.4 % over the past year, with a market capitalization of USD 45.47M.

Serina Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Serina Therapeutics, Inc. key figures

Previous close

USD 1.71 (2026-10-14)

1-year change

-66.4 %

Market cap

USD 45.47M

Enterprise value

USD 26.2M

P/E ratio (trailing)

-0.97

P/E ratio (forward)

-1.71

EPS (trailing)

-1.84

EPS (forward)

-1.05

PEG ratio

n/a

Price to book

2.43

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.57

Employees

16

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Serina Therapeutics, Inc. and compare it with other stocks.